Cell-free DNA in the supernatant of pleural effusion as bio-source for diagnostic biomarker tests 225 6 Molecular diagnostics performed in clinical practice Time of sampling Clinical application Assay Results Tumor cell percentage (estimated by pathologist on Giemsa slide) low durable response to osimertinib treatment very low progressive disease during erlotinib treatment very low very low progressive disease during erlotinib treatment unknown unknown unknown unknown 50% 5-10% molecular profiling fragment analysis EGFR exon 19 del 30% 1% T790M not possible no tumor no tumor durable response to osimertinib treatment no tumor no tumor no tumor unknown unknown
RkJQdWJsaXNoZXIy MTk4NDMw